Literature DB >> 11586012

Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris.

B Dreno1, D Moyse, M Alirezai, P Amblard, N Auffret, C Beylot, I Bodokh, M Chivot, F Daniel, P Humbert, J Meynadier, F Poli.   

Abstract

BACKGROUND: In addition to tetracyclines, zinc may constitute an alternative treatment in inflammatory lesions of acne.
OBJECTIVE: To evaluate the place of zinc gluconate in relation to antibiotics in the treatment of acne vulgaris.
METHODS: Zinc was compared to minocycline in a multicenter randomized double-blind trial. 332 patients received either 30 mg elemental zinc or 100 mg minocycline over 3 months. The primary endpoint was defined as the percentage of the clinical success rate on day 90 (i.e. more than 2/3 decrease in inflammatory lesions, i.e. papules and pustules).
RESULTS: This clinical success rate was 31.2% for zinc and 63.4% for minocycline. Minocycline nevertheless showed a 9% superiority in action at 1 month and one of 17% at 3 months, with respect to the mean change in lesion count. Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline).
CONCLUSION: Minocycline and zinc gluconate are both effective in the treatment of inflammatory acne, but minocycline has a superior effect evaluated to be 17% in our study. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586012     DOI: 10.1159/000051728

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  13 in total

1.  The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.

Authors:  Whitney Valins; Sadegh Amini; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

Review 2.  Treatment of acne vulgaris during pregnancy and lactation.

Authors:  Y L Kong; H L Tey
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

3.  Over-the-counter Acne Treatments: A Review.

Authors:  Ashley Decker; Emmy M Graber
Journal:  J Clin Aesthet Dermatol       Date:  2012-05

4.  Zinc: an essential micronutrient.

Authors:  Robert B Saper; Rebecca Rash
Journal:  Am Fam Physician       Date:  2009-05-01       Impact factor: 3.292

Review 5.  Minocycline for acne vulgaris: efficacy and safety.

Authors:  Sarah E Garner; Anne Eady; Cathy Bennett; John Norman Newton; Karen Thomas; Catalin Mihai Popescu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  Cutaneous induction of corticotropin releasing hormone by Propionibacterium acnes extracts.

Authors:  Olivia Isard; Anne-Chantal Knol; Nathalie Castex-Rizzi; Amir Khammari; Marie Charveron; Brigitte Dréno
Journal:  Dermatoendocrinol       Date:  2009-03

Review 7.  Can tetracyclines ensure help in multiple sclerosis immunotherapy?

Authors:  Pedro Víctor-Carvalho; Rodolfo Thome; Catarina Rapôso
Journal:  J Clin Transl Res       Date:  2021-02-03

8.  Susceptibility of Propionibacterium acnes isolated from patients with acne vulgaris to zinc ascorbate and antibiotics.

Authors:  Katsuhiro Iinuma; Norihisa Noguchi; Hidemasa Nakaminami; Masanori Sasatsu; Setsuko Nishijima; Isami Tsuboi
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-10-05

9.  Effect of dietary zinc oxide on morphological characteristics, mucin composition and gene expression in the colon of weaned piglets.

Authors:  Ping Liu; Robert Pieper; Juliane Rieger; Wilfried Vahjen; Roger Davin; Johanna Plendl; Wilfried Meyer; Jürgen Zentek
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 10.  Zinc therapy in dermatology: a review.

Authors:  Mrinal Gupta; Vikram K Mahajan; Karaninder S Mehta; Pushpinder S Chauhan
Journal:  Dermatol Res Pract       Date:  2014-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.